Related Experiment Video
Updated: Apr 9, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
Idarucizumab for Dabigatran Reversal
Charles V Pollack1, Paul A Reilly, John Eikelboom
1From Pennsylvania Hospital, Philadelphia (C.V.P.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (P.A.R., R.D., B.W.); McMaster University (J.E., J.I.W.) and Thrombosis and Atherosclerosis Research Institute (J.I.W.) - both in Hamilton, ON, Canada; Boehringer Ingelheim Pharma, Biberach (S.G., J.S.) and Ingelheim (J.K.), Klinikum Frankfurt Höchst, Frankfurt am Main, and Heidelberg University Hospital, Heidelberg (T.S.) - all in Germany; University of Leuven, Leuven, Belgium (P.V.); Northwestern University, Chicago (R.A.B.); Leiden University Medical Center, Leiden (M.V.H.), and University Medical Center Groningen, Groningen, (P.W.K.) - both in the Netherlands; Boston University School of Medicine, Boston (E.M.H.); Duke University Medical Center, Durham, NC (J.H.L.); Brown Medical School and Rhode Island Hospital, Providence, RI (F.W.S.); and Tuen Mun Hospital, Tuen Mun, NT, Hong Kong (C.-W.K.).
Idarucizumab effectively reversed dabigatran
Area of Science:
- Pharmacology
- Hematology
Background:
- Lack of specific reversal agents for novel oral anticoagulants.
- Development of idarucizumab, a monoclonal antibody fragment, targeting dabigatran reversal.
Purpose of the Study:
- To evaluate the safety and efficacy of idarucizumab in reversing dabigatran's anticoagulant effects.
- To assess idarucizumab's impact on hemostasis in patients with serious bleeding or requiring urgent procedures.
Main Methods:
- Prospective cohort study involving 90 patients receiving 5g intravenous idarucizumab.
- Primary endpoint: maximum percentage reversal of dabigatran's anticoagulant effect within 4 hours.
- Secondary endpoint: restoration of hemostasis, assessed via laboratory tests and clinical evaluation.
Main Results:
- Complete reversal of dabigatran's anticoagulant effect in 100% of patients within minutes.
- Normalization of dilute thrombin time and ecarin clotting time in 88-98% of patients.
- Restoration of hemostasis observed in patients with bleeding and during urgent procedures.
Conclusions:
- Idarucizumab provides rapid and complete reversal of dabigatran's anticoagulant activity.
- The reversal agent demonstrates significant potential for managing dabigatran-related emergencies.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Depolarizing Blockers: Pharmocokinetics
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

